102 related articles for article (PubMed ID: 23785719)
1. Summaries for patients. Treatment of idiopathic pulmonary fibrosis with ambrisentan.
Ann Intern Med; 2013 May; 158(9):I-32. PubMed ID: 23785719
[No Abstract] [Full Text] [Related]
2. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Nathan SD; Wells AU; Collard HR; Costabel U; Richeldi L; de Andrade J; Khalil N; Morrison LD; Lederer DJ; Shao L; Li X; Pedersen PS; Montgomery AB; Chien JW; O'Riordan TG;
Ann Intern Med; 2013 May; 158(9):641-9. PubMed ID: 23648946
[TBL] [Abstract][Full Text] [Related]
3. Ambrisentan (Letairis) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2007 Oct; 49(1272):87-8. PubMed ID: 17938611
[No Abstract] [Full Text] [Related]
4. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
6. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.
Chung L; Ball K; Yaqub A; Lingala B; Fiorentino D
J Am Acad Dermatol; 2014 Aug; 71(2):400-1. PubMed ID: 25037794
[No Abstract] [Full Text] [Related]
7. Bilateral cotton wool spots after use of an endothelin receptor antagonist.
Khan MA; Pitcher JD; Kawut SM; Ho AC
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):156-9. PubMed ID: 24459200
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
9. Biological target proves disappointing in IPF.
Burki TK
Lancet Respir Med; 2013 Jun; 1(4):289. PubMed ID: 24429150
[No Abstract] [Full Text] [Related]
10. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
11. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study.
Parisi S; Peroni CL; Laganà A; Scarati M; Ambrogio F; Bruzzone M; Fusaro E
Rheumatology (Oxford); 2013 Jun; 52(6):1142-4. PubMed ID: 23463806
[No Abstract] [Full Text] [Related]
13. Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis.
Sumida H; Asano Y; Hatano M; Aozasa N; Toyama T; Akamata K; Miyazaki M; Taniguchi T; Takahashi T; Ichimura Y; Noda S; Kuwano Y; Yanaba K; Sato S
Mod Rheumatol; 2016; 26(3):454-7. PubMed ID: 24593173
[TBL] [Abstract][Full Text] [Related]
14. Ambrisentan.
Newman JH; Kar S; Kirkpatrick P
Nat Rev Drug Discov; 2007 Sep; 6(9):697-8. PubMed ID: 17907344
[No Abstract] [Full Text] [Related]
15. Effects of ambrisentan in a patient affected by combined pulmonary fibrosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular findings.
Roccia F; Campolo B; Gallelli L; Spaccarotella C; Mongiardo A; Falcone D; Savino R; Pelaia G; Indolfi C; Maselli R
Clin Drug Investig; 2013 Jun; 33(6):451-7. PubMed ID: 23605508
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.
Prescrire Int; 2009 Apr; 18(100):54. PubMed ID: 19585715
[TBL] [Abstract][Full Text] [Related]
17. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
18. Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
Sakao S
Respir Investig; 2020 Jul; 58(4):230-231. PubMed ID: 32279941
[No Abstract] [Full Text] [Related]
19. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
Ben-Yehuda O; Pizzuti D; Brown A; Littman M; Gillies H; Henig N; Peschel T
J Am Coll Cardiol; 2012 Jul; 60(1):80-1. PubMed ID: 22578922
[No Abstract] [Full Text] [Related]
20. An update on the use of ambrisentan in pulmonary arterial hypertension.
D'Alto M
Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
